Active Ingredient History
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anemia, Refractory (Phase 2)
Brain Neoplasms (Phase 1)
Brain Stem Neoplasms (Phase 1)
Breast Diseases (Phase 1)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 2)
Bronchial Neoplasms (Phase 1)
Burkitt Lymphoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)
Carcinoma, Renal Cell (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Digestive System Neoplasms (Phase 1)
Drug Interactions (Phase 1)
Endocrine Gland Neoplasms (Phase 1)
Endometrial Neoplasms (Phase 2)
Epigenetic Repression (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Glioma (Phase 1)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 2)
Intraocular Lymphoma (Phase 1)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 1)
Leukemia, Eosinophilic, Acute (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1)
Lymphomatoid Granulomatosis (Phase 1)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Histologic Type (Phase 1)
Neoplasms, Glandular and Epithelial (Phase 1)
Neuroendocrine Tumors (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Respiratory Tract Neoplasms (Phase 1)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Thoracic Neoplasms (Phase 1)
Thrombocytopenia (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Volunteers (Phase 1)
Waldenstrom Macroglobulinemia (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue